The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases

Modulation of the low affinity adenosine receptor subtype, the A2b adenosine receptor (A2bAR), has gained interest as a therapeutic target in various pathologic areas associated with cardiovascular disease. The actions of the A2bAR are diverse and at times conflicting depending on cell and tissue type and the timing of activation or inhibition of the receptor. The A2bAR is a promising and exciting pharmacologic target, however, a thorough understanding of A2bAR action is necessary to reach the therapeutic potential of this receptor. This review will focus on the role of the A2bAR in various cardiovascular and metabolic pathologies in which the receptor is currently being studied. We will illustrate the complexities of A2bAR signaling and highlight areas of research with potential for therapeutic development. J. Cell. Physiol. 230: 2891–2897, 2015. © 2015 Wiley Periodicals, Inc.

[1]  K. Ravid,et al.  An Adenosine Receptor-Krüppel-like Factor 4 Protein Axis Inhibits Adipogenesis* , 2014, The Journal of Biological Chemistry.

[2]  M. Koupenova,et al.  The Macrophage A2b Adenosine Receptor Regulates Tissue Insulin Sensitivity , 2014, PloS one.

[3]  J. Linden,et al.  The role of adenosine signaling in sickle cell therapeutics. , 2014, Hematology/oncology clinics of North America.

[4]  Z. Nemeth,et al.  A2B Adenosine Receptors Prevent Insulin Resistance by Inhibiting Adipose Tissue Inflammation via Maintaining Alternative Macrophage Activation , 2014, Diabetes.

[5]  Wenzheng Zhang,et al.  Elevated Ecto-5'-nucleotidase-Mediated Increased Renal Adenosine Signaling Via A2B Adenosine Receptor Contributes to Chronic Hypertension , 2013, Circulation research.

[6]  A. IJzerman,et al.  Adenosine A2B Receptor Agonism Inhibits Neointimal Lesion Development After Arterial Injury in Apolipoprotein E–Deficient Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[7]  N. LeBrasseur,et al.  The A2b Adenosine Receptor Modulates Glucose Homeostasis and Obesity , 2012, PloS one.

[8]  T. Blackwell,et al.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  T. Eckle,et al.  Adora2b Signaling on Bone Marrow Derived Cells Dampens Myocardial Ischemia-Reperfusion Injury , 2012, Anesthesiology.

[10]  C. Borchers,et al.  Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch critical for myocardial adaptation to ischemia , 2012, Nature Medicine.

[11]  M. Koupenova,et al.  A2b Adenosine Receptor Regulates Hyperlipidemia and Atherosclerosis , 2012, Circulation.

[12]  Ying Sun,et al.  A novel mechanism of control of NF&kgr;B activation and inflammation involving A2B adenosine receptors , 2012, Journal of Cell Science.

[13]  W. Gause,et al.  Adenosine promotes alternative macrophage activation via A2A and A2B receptors , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  C. Weber,et al.  Atherosclerosis: current pathogenesis and therapeutic options , 2011, Nature Medicine.

[15]  C. Müller,et al.  Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists. , 2011, ACS medicinal chemistry letters.

[16]  K. Ravid,et al.  A Role for the Low-Affinity A2B Adenosine Receptor in Regulating Superoxide Generation by Murine Neutrophils , 2011, Journal of Pharmacology and Experimental Therapeutics.

[17]  D. Galas,et al.  Interleukin-6 Contributes to Inflammation and Remodeling in a Model of Adenosine Mediated Lung Injury , 2011, PloS one.

[18]  E. Jackson,et al.  2',3'-cAMP, 3'-AMP, and 2'-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors. , 2011, American journal of physiology. Heart and circulatory physiology.

[19]  P. Libby,et al.  Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.

[20]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[21]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[22]  G. Hansson,et al.  The immune system in atherosclerosis , 2011, Nature Immunology.

[23]  Peter Carmeliet,et al.  Hypoxia and inflammation. , 2011, The New England journal of medicine.

[24]  J. Pankow,et al.  Links Between Insulin Resistance, Adenosine A2B Receptors, and Inflammatory Markers in Mice and Humans , 2011, Diabetes.

[25]  G. Dangas,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[26]  G. Gross,et al.  Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor. , 2010, Journal of molecular and cellular cardiology.

[27]  K. Ravid,et al.  Tissue-derived proinflammatory effect of adenosine A2B receptor in lung ischemia-reperfusion injury. , 2010, The Journal of thoracic and cardiovascular surgery.

[28]  E. Vizi,et al.  A2B Adenosine Receptors Protect against Sepsis-Induced Mortality by Dampening Excessive Inflammation , 2010, The Journal of Immunology.

[29]  D. Mitchell,et al.  Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice. , 2010, American journal of respiratory cell and molecular biology.

[30]  A. Zernecke,et al.  Chemokines in the vascular inflammatory response of atherosclerosis. , 2010, Cardiovascular research.

[31]  F. Geissmann,et al.  Monocytes in atherosclerosis: subsets and functions , 2010, Nature Reviews Cardiology.

[32]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[33]  K. Varani,et al.  Adenosine Modulates HIF-1&agr;, VEGF, IL-8, and Foam Cell Formation in a Human Model of Hypoxic Foam Cells , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[34]  H. Criswell,et al.  Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. , 2009, Journal of molecular and cellular cardiology.

[35]  Michael R. Blackburn,et al.  Enhanced Airway Inflammation and Remodeling in Adenosine Deaminase-Deficient Mice Lacking the A2B Adenosine Receptor1 , 2009, The Journal of Immunology.

[36]  R. Webb,et al.  Vascular Smooth Muscle Cell Signaling Mechanisms for Contraction to Angiotensin II and Endothelin-1. , 2009, Journal of the American Society of Hypertension : JASH.

[37]  M. Koupenova,et al.  TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. , 2008, Biochemical and biophysical research communications.

[38]  T. Eckle,et al.  A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. , 2008, The Journal of clinical investigation.

[39]  R. Lehmann,et al.  Hypoxia-Inducible Factor-1 Is Central to Cardioprotection: A New Paradigm for Ischemic Preconditioning , 2008, Circulation.

[40]  S. Srinivasan,et al.  Blockade of adenosine A2B receptors ameliorates murine colitis , 2008, British journal of pharmacology.

[41]  Mathijs Groeneweg,et al.  Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. , 2008, Journal of the American College of Cardiology.

[42]  David A. Lustig,et al.  Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. , 2008, Journal of medicinal chemistry.

[43]  T. Eckle,et al.  A2B adenosine receptor dampens hypoxia-induced vascular leak. , 2008, Blood.

[44]  I. Biaggioni,et al.  Effect of A2B Adenosine Receptor Gene Ablation on Adenosine-Dependent Regulation of Proinflammatory Cytokines , 2008, Journal of Pharmacology and Experimental Therapeutics.

[45]  M. Koupenova,et al.  The A2b adenosine receptor protects against vascular injury , 2008, Proceedings of the National Academy of Sciences.

[46]  B. Fredholm,et al.  A1 receptor deficiency causes increased insulin and glucagon secretion in mice. , 2007, Biochemical pharmacology.

[47]  B B Fredholm,et al.  Adenosine, an endogenous distress signal, modulates tissue damage and repair , 2007, Cell Death and Differentiation.

[48]  Y. Lou,et al.  RNA interference for HIF-1α inhibits foam cells formation in vitro , 2007 .

[49]  E. Vizi,et al.  Adenosine receptor activation ameliorates type 1 diabetes , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  C. Ledent,et al.  Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.

[51]  A. Nadeem,et al.  Effect of a Specific and Selective A2B Adenosine Receptor Antagonist on Adenosine Agonist AMP and Allergen-Induced Airway Responsiveness and Cellular Influx in a Mouse Model of Asthma , 2007, Journal of Pharmacology and Experimental Therapeutics.

[52]  X. Hua,et al.  Enhanced mast cell activation in mice deficient in the A2b adenosine receptor , 2007, The Journal of experimental medicine.

[53]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[54]  C. Müller,et al.  The impact of adenosine and A2B receptors on glucose homoeostasis , 2006, The Journal of pharmacy and pharmacology.

[55]  Hongyan Zhong,et al.  Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. , 2006, The Journal of clinical investigation.

[56]  Pál Pacher,et al.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases , 2006, Nature Reviews Drug Discovery.

[57]  M. Koupenova,et al.  The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. , 2006, The Journal of clinical investigation.

[58]  E. Vizi,et al.  Adenosine Augments IL-10 Production by Macrophages through an A2B Receptor-Mediated Posttranscriptional Mechanism1 , 2005, The Journal of Immunology.

[59]  Z. Ge,et al.  Adenosine Inhibits Tumor Necrosis Factor-α Release from Mouse Peritoneal Macrophages via A2A and A2B but Not the A3 Adenosine Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[60]  T. Ziegler,et al.  TNF-α upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis , 2005, Cellular and Molecular Life Sciences.

[61]  C. Grines,et al.  Coronary Stent Restenosis in Patients Treated With Cilostazol , 2005, Circulation.

[62]  G. Montalescot,et al.  Drug eluting stents: an updated meta-analysis of randomised controlled trials , 2005, Heart.

[63]  Tiejuan Mi,et al.  Adenosine-Dependent Pulmonary Fibrosis in Adenosine Deaminase-Deficient Mice1 , 2005, The Journal of Immunology.

[64]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[65]  J. Linden.  Adenosine in Tissue Protection and Tissue Regeneration , 2005, Molecular Pharmacology.

[66]  B. Cronstein,et al.  Th1 Cytokines Regulate Adenosine Receptors and Their Downstream Signaling Elements in Human Microvascular Endothelial Cells 1 , 2003, The Journal of Immunology.

[67]  K. Jacobson,et al.  Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium , 2003, The Journal of experimental medicine.

[68]  H. Harada,et al.  Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes. , 2003, European journal of pharmacology.

[69]  G. Burnstock.  Purinergic Signaling and Vascular Cell Proliferation and Death , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[70]  Geoffrey Burnstock,et al.  Purinergic Signalling: ATP Release , 2001, Neurochemical Research.

[71]  M. Si-Tahar,et al.  Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. , 2001, The Journal of clinical investigation.

[72]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[73]  B. Fredholm,et al.  Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.

[74]  T. Inoue,et al.  2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor. , 2001, Journal of medicinal chemistry.

[75]  G. Burnstock,et al.  Increased release of ATP from endothelial cells during acute inflammation , 1998, Inflammation Research.

[76]  A. Becker,et al.  Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. , 1998, Circulation.

[77]  J. Isner,et al.  Histopathology of in-stent restenosis in patients with peripheral artery disease. , 1997, Circulation.

[78]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[79]  A. Gubitz,et al.  Tissue distribution of adenosine receptor mRNAs in the rat , 1996, British journal of pharmacology.

[80]  G. Burnstock,et al.  Contribution of P1 (A2b subtype) and P2‐purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed , 1995, British journal of pharmacology.

[81]  J. Downey,et al.  Adenosine-induced vasodilation: receptor characterization in pulmonary circulation. , 1995, The American journal of physiology.

[82]  P. L. Martin,et al.  The endothelium of the rat renal artery plays an obligatory role in A2 adenosine receptor-mediated relaxation induced by 5'-N-ethylcarboxamidoadenosine and N6-cyclopentyladenosine. , 1994, The Journal of pharmacology and experimental therapeutics.

[83]  M. Miller,et al.  Comparative effects of a selective adenosine A2 receptor agonist, CGS 21680, and nitroprusside in vascular smooth muscle. , 1991, European journal of pharmacology.

[84]  R. Jennings,et al.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.

[85]  A. Szent-Györgyi,et al.  The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart 1 , 1929, The Journal of physiology.

[86]  Dl Hoyert,et al.  National Vital Statistics Reports NCHS.pdf , 2012 .

[87]  M. Koupenova,et al.  The A 2 b Adenosine Receptor Regulates Hyperlipidemia and Atherosclerosis , 2011 .

[88]  K. Varani,et al.  Adenosine receptors in health and disease. , 2011, Advances in pharmacology.

[89]  Y. Lou,et al.  RNA interference for HIF-1alpha inhibits foam cells formation in vitro. , 2007, European journal of pharmacology.

[90]  L. Belardinelli,et al.  Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. , 2005, American journal of respiratory cell and molecular biology.

[91]  I. Biaggioni,et al.  A2B Adenosine Receptors Increase Cytokine Release by Bronchial Smooth Muscle Cells , 2004 .

[92]  L. Belardinelli,et al.  Synergy between A 2 B Adenosine Receptors and Hypoxia in Activating Human Lung Fibroblasts , 2004 .

[93]  E. Jackson,et al.  A2B Receptors Mediate Antimitogenesis in Vascular Smooth Muscle Cells , 2000 .

[94]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[95]  E. Jackson,et al.  A 2 B Receptors Mediate Antimitogenesis in Vascular Smooth Muscle Cells , 2000 .

[96]  E. Jackson,et al.  Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells. , 1999, Hypertension.

[97]  E. Jackson,et al.  Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. , 1998, Hypertension.

[98]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.